Profile data is unavailable for this security.
About the company
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
- Revenue in SEK (TTM)758.97m
- Net income in SEK153.08m
- Incorporated1994
- Employees236.00
- LocationCellaVision ABMobilvagen 12LUND 223 62SwedenSWE
- Phone+46 464601600
- Fax+46 462864470
- Websitehttps://www.cellavision.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Technologies SA | 248.78m | -234.70m | 1.88bn | 211.00 | -- | -- | -- | 7.56 | -1.16 | -1.16 | 1.23 | -2.08 | 0.8894 | -12.98 | 3.92 | 96,717.84 | -83.91 | -60.70 | -- | -232.35 | 102.73 | 102.32 | -94.35 | -97.73 | 0.3543 | -26.56 | -- | -- | 3.25 | 20.72 | -9.83 | -- | 43.77 | -- |
| Affluent Medical SAS | 43.95m | -157.35m | 2.26bn | 76.00 | -- | 6.65 | -- | 51.36 | -0.3759 | -0.3759 | 0.1051 | 0.5365 | 0.0709 | -- | 0.9541 | 59,681.16 | -25.40 | -23.76 | -32.61 | -27.59 | 1.34 | -226.93 | -358.01 | -1,815.40 | -- | -924.30 | 0.5030 | -- | -- | -- | 5.84 | -- | -- | -- |
| Prim SA | 2.57bn | 155.32m | 2.36bn | 954.00 | 14.17 | 1.67 | 8.68 | 0.921 | 0.9176 | 0.9176 | 14.13 | 7.80 | 1.17 | 1.97 | 4.17 | 251,008.80 | 7.09 | 6.27 | 10.40 | 8.50 | 38.77 | 37.70 | 6.05 | 5.85 | 1.20 | 144.87 | 0.1399 | 63.10 | 7.68 | 9.08 | -13.83 | -0.5366 | 13.50 | 6.35 |
| Tristel Plc | 567.53m | 81.11m | 2.37bn | 265.00 | 29.29 | 5.86 | 20.56 | 4.18 | 0.1383 | 0.1383 | 0.9676 | 0.6915 | 1.04 | 1.93 | 5.81 | 175,328.30 | 14.85 | 9.60 | 17.57 | 11.09 | 80.62 | 80.90 | 14.29 | 11.04 | 2.96 | -- | 0.1512 | 120.71 | 10.80 | 7.96 | 2.33 | 5.42 | -3.59 | 18.10 |
| Onward Medical NV | 11.87m | -412.53m | 2.47bn | 102.00 | -- | 6.67 | -- | 208.52 | -0.866 | -0.866 | 0.0249 | 0.6209 | 0.0215 | -- | 9.11 | 10,901.96 | -74.86 | -55.03 | -92.84 | -61.19 | 77.16 | -- | -3,475.81 | -39,652.37 | 4.30 | -17.13 | 0.352 | -- | 236.76 | -- | 1.26 | -- | 3.88 | -- |
| Stratec SE | 2.74bn | 167.07m | 2.65bn | 1.42k | 15.84 | 1.03 | 7.19 | 0.9654 | 1.29 | 1.29 | 21.13 | 19.75 | 0.5825 | 1.32 | 5.65 | 177,177.20 | 3.55 | 6.72 | 4.24 | 7.96 | 29.09 | 28.41 | 6.09 | 9.63 | 1.65 | 6.85 | 0.3552 | 37.35 | -4.73 | 3.76 | 4.24 | 2.35 | -7.49 | -6.51 |
| Medistim ASA | 635.76m | 135.43m | 3.64bn | 154.00 | 26.83 | 9.12 | 22.68 | 5.73 | 7.79 | 7.79 | 36.56 | 22.91 | 1.25 | 0.7679 | 9.67 | 4,341,637.00 | 26.72 | 21.98 | 33.09 | 27.19 | 81.21 | 78.66 | 21.30 | 20.32 | 2.03 | -- | 0.0484 | 85.04 | 6.88 | 9.12 | 0.0087 | 8.11 | 12.53 | 16.89 |
| CellaVision AB | 758.97m | 153.08m | 3.70bn | 236.00 | 24.18 | 4.17 | 19.24 | 4.88 | 6.42 | 6.42 | 31.82 | 37.21 | 0.7201 | 2.02 | 6.80 | -- | 14.52 | 14.71 | 16.22 | 16.96 | 68.50 | 68.38 | 20.17 | 19.85 | 2.97 | 25.88 | 0.0281 | 41.97 | 4.94 | 9.99 | 8.78 | 11.34 | 20.76 | 29.67 |
| IVF Hartmann Holding AG | 1.86bn | 222.08m | 3.92bn | 309.00 | 17.68 | 2.31 | 13.88 | 2.11 | 7.92 | 7.92 | 66.39 | 60.57 | 0.8964 | 3.28 | 7.88 | 526,221.10 | 10.69 | 7.90 | 12.91 | 9.68 | 55.71 | 54.06 | 11.93 | 9.13 | 3.79 | -- | 0.0042 | 48.54 | 7.33 | 2.85 | 34.02 | 10.78 | -28.94 | 19.92 |
| COLTENE Holding AG | 2.81bn | 167.14m | 4.03bn | 1.18k | 24.13 | 3.82 | 16.40 | 1.43 | 2.40 | 2.40 | 40.22 | 15.13 | 1.31 | 1.34 | 6.40 | 204,684.50 | 7.80 | 10.59 | 14.26 | 18.43 | 66.11 | 62.19 | 5.95 | 7.64 | 0.7043 | 7.62 | 0.3606 | 85.66 | 3.06 | -1.79 | 71.31 | 0.4306 | -15.45 | 10.76 |
| Ion Beam Applications SA | 6.37bn | 181.48m | 5.14bn | 2.10k | 28.01 | 3.92 | 16.34 | 0.807 | 0.5677 | 0.5677 | 20.17 | 4.06 | 0.9756 | 2.73 | 3.28 | 281,693.60 | 2.78 | 1.50 | 12.03 | 4.64 | 31.21 | 34.39 | 2.85 | 2.15 | 0.6209 | 7.41 | 0.3631 | 70.81 | 6.75 | 12.01 | 201.57 | 3.99 | 7.69 | 25.86 |
| Revenio Group Oyj | 1.17bn | 185.71m | 5.30bn | 247.00 | 28.44 | 4.31 | 22.76 | 4.52 | 0.654 | 0.654 | 4.12 | 4.31 | 0.7515 | 3.05 | 7.26 | 444,129.60 | 11.92 | 14.00 | 14.23 | 17.40 | 70.92 | 70.95 | 15.86 | 19.38 | 1.63 | 9.66 | 0.0969 | -- | 5.97 | 12.43 | -5.93 | 5.42 | 22.19 | -- |
| Lumibird SA | 2.30bn | 114.49m | 5.47bn | 1.07k | 47.75 | 2.56 | 16.84 | 2.37 | 0.4775 | 0.4775 | 9.61 | 8.90 | 0.5077 | 0.9593 | 4.42 | 202,198.50 | 2.52 | 2.51 | 3.11 | 3.17 | 63.89 | 61.89 | 4.97 | 4.90 | 1.64 | 3.16 | 0.4583 | 0.00 | 1.75 | 13.34 | -20.08 | -8.38 | 15.27 | -- |
Data as of Feb 20 2026. Currency figures normalised to CellaVision AB's reporting currency: Swedish Krona SEK
30.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 10 Feb 2026 | 1.18m | 4.95% |
| SEB Funds ABas of 30 Jan 2026 | 1.10m | 4.60% |
| Invesco Advisers, Inc.as of 30 Dec 2024 | 854.27k | 3.58% |
| Fj�rde AP-fondenas of 30 Sep 2025 | 722.67k | 3.03% |
| Alcur Fonder ABas of 30 Sep 2025 | 654.77k | 2.75% |
| AMF Fonder ABas of 30 Sep 2025 | 594.30k | 2.49% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 561.75k | 2.36% |
| Candriam Belgium SAas of 31 May 2024 | 537.06k | 2.25% |
| Financi�re de l'�chiquier SAas of 31 Mar 2025 | 531.56k | 2.23% |
| Alta Rocca Asset Management SASas of 30 Sep 2025 | 501.95k | 2.10% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
